E. I. du Pont de Nemours and Company
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From E. I. du Pont de Nemours and Company
A recent forum in South Korea heard from a venture capital executive about the changing IPO and financing environment and how bioventures might be able to cope with these changes.
Korean companies, including large conglomerates and non-biopharmas, are increasingly jumping into biologics manufacturing through cross-border acquisitions following the successes of Samsung and SK.
The head of the US arm of a major Korean government development institute talks to Scrip about why biotechs and pharma firms are flocking to Boston, how the organization is providing support and what the main challenges are.
US FDA told the company to add a warning to the label in late January, about a month before the generic refill cartridge was approved.
- Other Names / Subsidiaries